Lite Strategy (LITS) Profit After Tax (2010 - 2026)
Lite Strategy (LITS) posted quarterly Profit After Tax of -$23.7 million for Q1 2026, down 820.87% year-over-year from $3.3 million in Q1 2025, and up 23.07% quarter-over-quarter from -$30.8 million in Q4 2025.
Lite Strategy (LITS) Profit After Tax (2010 - 2026) Analysis & Trends
Lite Strategy's Profit After Tax history runs 17 years deep, the most recent figure standing at -$23.7 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 820.87% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at -$60.9 million (down 92.26% YoY), while the FY2025 annual figure was -$16.0 million, down 190.0% from the prior year.
- Profit After Tax for Q1 2026 stood at -$23.7 million, up from -$30.8 million in the prior quarter.
- The five-year high for Profit After Tax was $56.4 million in Q3 2023, with the low at -$30.8 million in Q4 2025.
- The 5-year median for Profit After Tax is -$9.1 million (2024), against an average of -$6.7 million.
- The sharpest annual moves came in 2023 and 2025: Profit After Tax jumped 439.11% in 2023, then plunged 1050.5% in 2025.
- Lite Strategy's Profit After Tax stood at $10.3 million in 2022, then tumbled by 207.9% to -$11.1 million in 2023, then jumped by 75.8% to -$2.7 million in 2024, then slumped by 1050.5% to -$30.8 million in 2025, then advanced by 23.07% to -$23.7 million in 2026.
- Business Quant data shows LITS's Profit After Tax at -$23.7 million in Q1 2026, -$30.8 million in Q4 2025, and -$3.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -23.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.69 Mn |
| Dec 31, 2025 | -30.80 Mn |
| Sep 30, 2025 | -3.64 Mn |
| Jun 30, 2025 | -2.74 Mn |
| Mar 31, 2025 | -2.57 Mn |
| Dec 31, 2024 | -2.68 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Jun 30, 2024 | -18.41 Mn |
| Mar 31, 2024 | -9.13 Mn |
| Dec 31, 2023 | -11.06 Mn |
| Sep 30, 2023 | 56.37 Mn |
| Jun 30, 2023 | -10.19 Mn |
| Mar 31, 2023 | -15.44 Mn |
| Dec 31, 2022 | 10.25 Mn |
| Sep 30, 2022 | -16.62 Mn |
| Jun 30, 2022 | -16.06 Mn |
| Mar 31, 2022 | -8.73 Mn |
| Dec 31, 2021 | -12.16 Mn |
| Sep 30, 2021 | -17.51 Mn |
| Jun 30, 2021 | -8.38 Mn |